SCO-Spondin-Derived Polypeptides for Treating Biobarrier Dysfunction
SCO-spondin-derived peptides restore and protect biological barriers by enhancing tight junction proteins, addressing dysfunctional barriers in diseases and preventing harmful substance crossing, thus effectively treating and preventing disease progression.
Patent Information
- Application Number
- JP2024532918
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-19
AI Technical Summary
Biological barriers, such as the blood-brain barrier, are dysfunctional in various diseases, leading to increased permeability and allowing harmful substances to cross, which is a causal factor in disease progression and can occur before symptoms appear, necessitating a therapeutic strategy to restore selective permeability.
SCO-spondin-derived peptides are administered to enhance tight junction proteins like claudin-5 and occludin, restoring and protecting the integrity of biological barriers by reducing permeability and improving tight junction function.
The peptides effectively increase electrical resistance, enhance claudin-5 and occludin expression, and decrease permeability to molecules, thereby restoring normal barrier function and preventing disease progression.
Smart Images

Figure 2024543220000022 
Figure 2024543220000023 
Figure 2024543220000024
Abstract
Description
[Technical field]
[0001] The present invention relates to a SCO-spondin derived polypeptide for treating biobarrier dysfunction. More specifically, the present invention relates to said polypeptide for treating biobarrier dysfunction in diseases or conditions including vascular disease, infectious disease, immune system hyperresponsiveness, inflammatory or autoimmune disease, chronic kidney disease, intestinal disease, macular degeneration, diabetic macular edema, epilepsy, neuropathic pain, CNS disease and disorder, and aging. The present invention also relates to said polypeptide for treating biobarrier dysfunction in situations where the disease or condition does not exist or has not yet been diagnosed. [Background technology]
[0002] Biological barriers protect organs and tissues from physical, chemical and biological damage, maintaining homeostasis. In addition, biological barriers are also represented at the interface between organs and the "outside", the latter being air in the case of mucosal barriers and body fluids in the case of vascular and brain barriers. Their main components are either endothelial or epithelial cell layers. The function of these cell layers is highly regulated by their microenvironment, including adjacent cell types, extracellular matrix or physical stimuli.
[0003] The function of biological barriers is known to be altered in many diseases. And it is becoming increasingly clear that barrier dysfunction is not only symptomatic but in some cases causally related to disease progression. Biological barrier dysfunction (1) may be causally related to disease development, (2) may occur in parallel with further physiopathological mechanisms, (3) may occur as a consequence of upstream events, thereby causing further complications, and (4) may precede the appearance of symptoms or diagnosis of disease. Thus, biological barriers are attractive therapeutic targets, and treatment of biological barrier dysfunction may be a therapeutic strategy applicable to a wide range of disorders.
[0004] The main physiological role of biological barriers is to maintain selective permeability between organs and tissues and their “outside.” As a result, the main pathophysiological mechanism involving biological barriers is the loss of selective permeability, which allows the unwanted diffusion of pathogens, toxins, cells, inflammatory mediators, plasma proteins or drugs into a tissue or organ.
[0005] Thus, the treatment of biological barrier dysfunction consists in improving or restoring the selective permeability of said barrier, which can also be described as restoring the integrity of the barrier or preventing the barrier from leaking.
[0006] Methods that could treat biological barrier dysfunction would be of great benefit to patients with conditions including vascular disease, infectious diseases, hyperresponsive immune system, inflammatory or autoimmune diseases, chronic kidney disease, intestinal disease, macular degeneration, diabetic macular edema, epilepsy, neuropathic pain, CNS diseases and disorders, and aging.
[0007] SCO-spondin derived peptides have been described for their neuroprotective and neuroregenerative properties. The use of SCO-spondin derived peptides for the treatment of spinal cord injury and tauopathy has been investigated in animal models. However, to date, no role has been suggested for their ability to treat biological barrier dysfunction.
[0008] Claudin-5 and / or occludin are abundant in barriers, including endothelial cells, originating from the brain ( Greene et al., 2019 ; Hashimoto et al., 2021 ), blood vessels ( Komarova et al., 2017 ), retina ( Arima et al., 2020 ; Hudson et al., 2019 ; van der Wijk et al., 2019 ), and lung ( Huang et al., 2016 ; Chen et al., 2013 ). [Prior art documents] [Patent documents]
[0009] [Patent Document 1] WO-99 / 03890 [Patent Document 2] U.S. Patent No. 6,995,140 [Patent Document 3] WO2018146283 No. [Patent Document 4] WO2017 / 051135 No. [Non-patent literature]
[0010] [Non-Patent Document 1] Sweeney et al., Physiol Rev, 2019 [Non-Patent Document 2] Montagne et al., Nature, 2020 [Non-Patent Document 3] Biophysical Journal, Volume 95, November 2008, Pages 4879-4889 Summary of the Invention [Means for solving the problem]
[0011] The inventors have surprisingly identified for the first time the ability of SCO-spondin derived peptides to treat or prevent certain bodily dysfunctions in humans and non-human animals. In a first embodiment, the bodily dysfunction is or comprises biological barrier dysfunction (or a defective or pathological biological barrier) or an increase in barrier permeability. In another embodiment, the bodily dysfunction is or comprises a change in the tight junction between adjacent cells forming the endothelial or epithelial layer of the biological barrier. In another embodiment, the bodily dysfunction is or comprises a decrease in transendothelial and / or transepithelial electrical resistance. In another embodiment, the bodily dysfunction is or comprises a deregulation of the expression or distribution of tight junction proteins, particularly claudin-5, or the expression of occludin. In another embodiment, the bodily dysfunction is or comprises a deregulation of transcompartment (i.e. two physiological compartments separated by a biological barrier) permeability or an increase in a specific compound or molecule.
[0012] The permeability of biological barriers includes transcellular and paracellular permeability. Transcellular permeability is mediated by membrane receptors and vesicles, while paracellular permeability depends on adhesion mechanisms between adjacent cells that form the endothelial or epithelial layer of the barrier. Among these adhesion mechanisms, tight junctions are an important factor in limiting paracellular permeability at the desired location.
[0013] Tight junctions are cell adhesions composed of multiple transmembrane proteins that directly interact through their extracellular components to link the membranes of two adjacent cell membranes to each other. Several classes of proteins participate in the tight junction complex, including members of the claudin family, which define the selectivity of paracellular permeability.
[0014] "Dysfunction of a barrier" means that the permeability of the barrier is altered relative to normal (i.e., the barrier in a healthy subject), which may be detrimental to good health, since this alteration may result in an altered or increased permeability and crossing of compounds, including inflammatory cytokines, fibrinogen and other (e.g., organic molecules, peptides, polypeptides, proteins, antibodies, viruses, etc.) blood components from the blood compartment to the parenchymal or fluid (e.g., cerebrospinal fluid) compartment, relative to a normal or healthy barrier. This dysfunction may be due in particular to a disturbance of the tight junctions between the endothelial and / or epithelial cells involved in the barrier, which leads to an altered or increased permeability.
[0015] According to the present invention, biological barrier dysfunction can be treated in situations where a disease or condition does not exist or has not yet been diagnosed. Peptide administration can have a protective or prophylactic effect against the development of a disease or disorder, or in situations where a disease or condition in a subject is known or suspected.
[0016] The present invention restores the permeability of normal physiological barriers or protects the permeability or function of normal physiological barriers. Permeability is restored if the subject recovers normal permeability, or if the subject recovers permeability as close as possible to that in healthy subjects, or if the subject being treated recovers a more functional barrier than in the absence of treatment. Permeability is protected (meaning the biological barrier is protected) if the peptide is capable of keeping permeability unchanged or maintaining permeability as close as possible to normal before, during, or during the development of a disease that may worsen barrier permeability. In one aspect, the peptide used in the present invention brings endothelial cells of the barrier into approximation, brings epithelial cells of the barrier into approximation, or brings endothelial and epithelial cells of the barrier into approximation. In this aspect, the tight junction is said to be restored or improved. In another aspect, the peptide used in the present invention induces an increase in claudin-5 and / or occludin levels at the surface of barrier endothelial cells and / or epithelial cells, in particular it allows claudin-5 present in vesicles to reach or spread on the surface of barrier endothelial cells and / or epithelial cell membranes (herein called claudin-5 distribution).The effect of said peptide on claudin-5 and / or occludin can be used as a marker of the positive effect of said peptide on barrier integrity and permeability, as in barrier models.It is also a marker of the effectiveness of peptide in treating biological barrier dysfunction, protecting biological barrier or reducing pathological biological barrier permeability.
[0017] Thus, in a first aspect, the present invention relates to one or more SCO-spondin derived peptides for use in the treatment of biological barrier dysfunction or for protecting the biological barrier.
[0018] Thus, one object of the present invention is a peptide having an amino acid sequence according to any one of SEQ ID NOs: 1 to 63, in particular NX210 or NX218, for use in the treatment of biological barrier dysfunction.
[0019] In one aspect, the peptide is for use in the treatment of biological barrier dysfunction, the peptide is for restoring or protecting (especially normal) physiological or biological barrier permeability, or the peptide is for reducing biological barrier permeability or pathological biological barrier permeability.
[0020] In one embodiment, the peptide is for use in the treatment of biological barrier dysfunction, the peptide is for restoring, protecting or improving tight junctions of endothelial and / or epithelial cells of the biological barrier, the effect being described as restoring or protecting physiological barrier permeability.
[0021] Another object of the present invention is a method for treating biological barrier dysfunction or protecting biological barrier in a subject in need thereof, comprising administering to said subject an effective amount of one or more SCO-spondin derived peptides. In one embodiment, said peptide has an amino acid sequence according to any one of SEQ ID NOs: 1-63, in particular the amino acid sequence of NX210 or NX218, for use in treating biological barrier dysfunction.
[0022] In one aspect, the method comprises administering the peptide, which restores or protects the permeability of a (particularly normal) physiological barrier or reduces the permeability of a biological barrier or the permeability of a pathological biological barrier.
[0023] In one embodiment, the method comprises administering said peptide, which restores, protects or improves tight junctions in endothelial and / or epithelial cells of a biological barrier, said effect accounting for restoring or protecting the permeability of a physiological barrier.
[0024] Another object of the present invention is the use of a peptide as disclosed herein for the manufacture of a medicament for treating or protecting a biological barrier or for reducing the permeability of a biological barrier, which object may include any one of the other aspects or features of the other objects defined herein.
[0025] In embodiments of these various aspects of the invention, the biological barrier is the blood-brain barrier. In another embodiment, it is the blood-spinal cord barrier. In another embodiment, it is the inner blood-retinal barrier. In another embodiment, it is the blood-cerebrospinal fluid barrier (BCSFB). In another embodiment, it is the pulmonary endothelial barrier. In another embodiment, it is the blood-parenchymal barrier. In another embodiment, it is the blood-fluid barrier. In another embodiment, two or more of these barriers are simultaneously relevant to the use or method of use according to the invention.
[0026] The impairment or dysfunction of the BBB in a subject (i.e., the BBB is eligible for this treatment) can be determined using several methods. These methods are currently available in the clinic and can be used in patients who have not been diagnosed or declared ill. Furthermore, as described below, these methods can also be used to verify the favorable effects of peptides when used to treat or protect biological barriers.
[0027] A first known method for the determination of dysfunction or impairment is the determination of the local BBB permeability constants Ktrans or K for a contrast agent, preferably the contrast agent gadolinium, identified by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) (Montagne et al., 2020). transThe aim of this study is to measure the K trans (representing the rate of movement of molecules from the plasma space across the barrier) for specific areas in the CNS. This can be done, for example, in the hippocampus in individuals with AD, the basal ganglia in individuals with PD (Sweeney et al., Physiol Rev, 2019; Montagne et al., Nature, 2020; Al-Bachari et al., 2020), the substantia nigra, or the posterior cortex.
[0028] K trans in the hippocampus (Montagne et al., 2020): Normal or healthy subjects: 1.2 × 10 -3 min -1 , ApoE4 carriers (especially those with AD): 1.6×10-3min -1 Level is 1.6×10-3min -1 In the above cases, a functional disorder is considered to exist.
[0029] K trans in the substantia nigra (SN): healthy subjects = approx. 0.3 × 10 -3 min -1 , subjects with PD = approximately 0.5 x 10 -3 min -1 The level is 0.4×10 -3 min -1 In the above cases, a functional disorder is considered to exist.
[0030] K trans in the posterior cortex (PC): healthy subjects = approx. 0.4 × 10 -3 min -1 , subjects with PD = approximately 0.5 x 10 -3 min -1 The level is 0.5×10 -3 min -1 In the above cases, a functional disorder is considered to exist.
[0031] The impairment or dysfunction of biological barriers, particularly the BBB and BCSFB, in a subject (i.e., eligible for this treatment) can also be determined by measuring the albumin index (Qalb=[CSF concentration / serum concentration]×1000, which is the ratio of the CSF albumin level or concentration to the serum albumin level or concentration). Albumin can also be measured by immunoturbidimetry. See Uher et al., 2015. An increase in Qalb is a sign of impairment of barriers, particularly the BBB and BCSFB. According to Uher et al., 2015, an impairment or dysfunction is present if the patient is under 40 years old and has QAlb>6.5, and over 40 years old and has QAlb>8. In healthy subjects, QAlb<6.5 under 40 years old and QAlb<8 over 40 years old. One can also consider Castellazzi et al. (2020), which provides a more accurate classification based on age, for example, in healthy subjects, QAlb<6.5 for ages 15-40, QAlb<8.0 for ages 41-60, and QAlb<9.0 for ages >60. Based on this classification, patients can be considered to have a disability or impaired function if they have QAlb>6.5 for ages 15-40, QAlb>8.0 for ages 41-60, and QAlb>9.0 for ages >60.
[0032] Other methods include measuring the levels of several markers in the CSF. These markers are brain-derived proteins present in the CSF, such as soluble PDGFRβ (platelet-derived growth factor BB), cyclophilin A and matrix metalloproteinase-9 (Sweeney et al., Physiol Rev, 2019; Montagne et al., Nature, 2020). BBB dysfunction correlates with an increase in one or more of these markers in the CSF. - PGDFRβ (Montagne et al., 2020): normal subjects: 500 ng / mL, apoE4-carrying subjects: 600 ng / mL. Levels above 600 ng / mL are considered herein to be dysfunctional. Measurements are performed as described in the cited literature using quantitative Western blot analysis. - Cyclophilin A (CypA) (Montagne et al., 2020): normal subjects: 60 ng / mL, apoE4-carrying subjects: 70 ng / mL. Levels above 70 ng / mL are considered dysfunctional herein. Measurements are performed as described in the cited literature using a Meso Scale Discovery (MSD) Imager with electrochemiluminescence detection, using the CypA assay described in the cited literature. - Matrix metalloproteinase-9 (MMP-9) (Montagne et al., 2020): normal subjects: 50 pg / mL, apoE4-carrying subjects: 100 pg / mL. Levels above 100 pg / mL are considered to be dysfunctional herein. Measurements are performed using the Human MMP-9 Ultra-sensitive Kit from MSD as described in the cited literature.
[0033] Other methods can be used to characterize barrier, particularly BBB, disorders or dysfunction, such as: - As already mentioned, increased regional BBB permeability constants, Ktrans for the contrast agent gadolinium, using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), e.g. in the hippocampus of individuals with AD or the basal ganglia of individuals with PD (Sweeney et al., Physiol Rev, 2019; Montagne et al., Nature, 2020); - Hypotenses identified by T2* MRI or susceptibility weighted imaging (SWI MRI) showing microbleeds (reflecting BBB breakdown) in the brains of individuals with MCI, early AD, ALS, and PD without dementia (Sweeney et al., Physiol Rev, 2019); - Decreased regional brain uptake of 2-deoxyglucose in individuals with MCI and early AD, using FDG-positron emission tomography (PET) as a clinical surrogate for brain glucose uptake (Sweeney et al., Physiol Rev, 2019).
[0034] In one aspect, the beneficial effect on barrier integrity or restoration, or restoration or reduction in permeability, can be determined using one, or a combination of two or more, of these methods.
[0035] Thus, a beneficial effect can be asserted, in particular, by measuring the levels of Ktrans, Qalb, PGDFRβ, Cyclophilin A, and / or MMP-9, and by the observation that the peptide allows to restore normal levels, to approach normal levels, or to reduce the permeability of Ktrans.
[0036] The beneficial effect of a treatment of the invention (after or during treatment) on BBB damage or dysfunction can be determined by measuring one or more of these markers.
[0037] In one embodiment, the Ktrans method and / or Qalb markers are used to determine the beneficial effect of the treatment of the invention (after or during treatment) on the impairment or dysfunction of biological barriers such as the BBB or BCSFB. There is a beneficial effect of the treatment if there is a decrease in the marker levels relative to the levels before treatment, or if the marker levels reflect a decrease in permeability, or if the levels measured after or during treatment are close to normal levels. The marker values are given in the detailed description. In one aspect, patients who may benefit from this treatment are determined or selected before treatment. The patients are or have been previously determined to have biological barrier impairment or dysfunction as described, altered tight junctions as described, abnormal claudin-5 and / or occludin levels as described. As such, altered tight junctions and abnormal claudin-5 and / or occludin levels can be indicative of barrier dysfunction, and abnormal claudin-5 and / or occludin levels can be indicative of altered tight junctions.
[0038] In a first embodiment, the dysfunction is detected by measuring the local barrier, in particular the BBB permeability constant Ktrans, for a contrast agent identified by DCE-MRI, preferably the contrast agent gadolinium. For example, a Ktrans level in the hippocampus of 1.6×10 -3 min -1 If the IL-10 level is equal to or greater than 1, dysfunction is present. See above for other values depending on the CNS region.
[0039] In another embodiment, the dysfunction is detected by measuring the ratio of serum albumin level to CSF albumin level, Qalb. The levels corresponding to the dysfunction are described above.
[0040] In another embodiment, dysfunction of the biological barrier, in particular the BBB, and thus the determination that the patient is eligible for treatment, is detected by measuring the levels of soluble PDGFRβ, cyclophilin A and / or matrix metalloproteinase-9 (MMP-9) in the CSF. Dysfunction is present if: - PGDFRβ level ≥ 600ng / mL. - Cyclophilin A level is 70 ng / mL or higher. - MMP-9 level greater than or equal to 100 pg / mL.
[0041] In another embodiment, the dysfunction is detected by measuring hypointensities identified by T2* MRI or SWI MRI, the levels corresponding to the dysfunction being described above.
[0042] In another embodiment, the dysfunction is detected by measuring regional brain uptake of 2-deoxyglucose using FDG-PET, the levels corresponding to the dysfunction being as described above.
[0043] In one embodiment, the impairment is determined using a combination of two or more of these methods.
[0044] In one embodiment, tight junction dysfunction is determined using a combination of two or more of these methods.
[0045] In one aspect, the biological barrier is the blood-brain barrier (BBB) and the patient suffers from a dysfunction of the biological barrier in a disease or condition including vascular disease, infectious disease, hyperresponsive immune system, inflammatory or autoimmune disease, chronic kidney disease, intestinal disease, macular degeneration, diabetic macular edema, epilepsy, neuropathic pain, CNS diseases and disorders, and aging.
[0046] In one embodiment, a patient is first tested as described to determine whether or not they have a dysfunction of the BBB (and are eligible for the treatment of the present invention), where the dysfunction is determined using a combination of two or more of the above methods.
[0047] In another embodiment, the dysfunction of a biological barrier is the BBB and no disease or condition has been diagnosed in the patient.
[0048] In another aspect, the present invention relates to one or more SCO-spondin derived peptides for use in the treatment of biological barrier tight junction dysfunction or for protecting said tight junctions.
[0049] In another aspect, the present invention relates to a method for treating biological barrier tight junction dysfunction or protecting said tight junctions in a subject in need thereof, comprising administering to said subject an effective amount of one or more SCO-spondin derived peptides.
[0050] In embodiments of these various aspects of the invention, the biological barrier is the blood-brain barrier. In another embodiment, it is the blood-spinal cord barrier. In another embodiment, it is the intra-blood-retinal barrier. In another embodiment, it is the blood-cerebrospinal fluid barrier. In another embodiment, it is the pulmonary endothelial barrier. In another embodiment, it is the blood-parenchymal barrier. In another embodiment, it is the blood-fluid barrier. In another embodiment, two or more of these barriers are simultaneously relevant to the use or method of use according to the invention.
[0051] As mentioned above, the beneficial effect of a treatment on BBB disorders can be determined using any one of the following markers, or any combination of at least two of them, and using known methods disclosed herein and described in the cited references: - Decreased regional BBB permeability constants, Ktrans to contrast agents, e.g. gadolinium, using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), e.g. in the hippocampus of individuals with AD or the basal ganglia of individuals with PD (Sweeney et al., Physiol Rev, 2019; Montagne et al., Nature, 2020); - Albumin index (Qalb), which is the ratio of serum albumin level to CSF albumin level in individuals with preclinical AD (without clinical signs and symptoms), mild cognitive impairment (MCI), AD with or without vascular risk factors, early PD before dementia, ALS, MS, etc. (Sweeney et al., Physiol Rev, 2019; Uher et al., 2015), - levels of brain-derived proteins present in the CSF, such as soluble PDGFRβ (platelet-derived growth factor BB), cyclophilin A and matrix metalloproteinase-9 (Sweeney et al., Physiol Rev, 2019; Montagne et al., Nature, 2020); - Hypointensities identified by T2* MRI or susceptibility weighted imaging (SWI MRI) showing microbleeds (reflecting BBB breakdown) in the brains of individuals with MCI, early AD, ALS, and PD without dementia (Sweeney et al., Physiol Rev, 2019) - Decreased regional brain uptake of 2-deoxyglucose in individuals with MCI and early AD, using FDG-positron emission tomography (PET) as a clinical surrogate for brain glucose uptake (Sweeney et al., Physiol Rev, 2019).
[0052] In one aspect, the beneficial effect on barrier integrity or restoration or on the decrease of pathological barrier permeability can be determined using one of these methods, or a combination of two or more. The beneficial effect exists when the peptide allows for the restoration to normal or for one or more levels as above to approach normal. The beneficial effect is also obtained when there is a significant progress towards normal of the level. The marker values that reflect the improvement of biological barrier, particularly biological barrier permeability, i.e. its decrease, are given in the detailed description, particularly for K trans and Qalb.
[0053] In one aspect, the biological barrier is the blood-brain barrier (BBB) and the patient is suffering from a central nervous system (CNS) disease, such as a neurodegenerative disease.
[0054] In one embodiment, a patient is first tested as described to determine whether or not they have BBB dysfunction, where the dysfunction is determined using a combination of two or more of the above methods. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0055] The CNS is protected by the blood-brain barrier (BBB), the blood-spinal cord barrier (BSCB), and the blood-cerebrospinal fluid barrier (BCSFB).
[0056] The BBB plays a major role in (1) regulating cerebral blood flow required for CNS homeostasis, (2) controlling the transport of glucose and oxygen as well as other metabolites from the blood to the brain, and (3) enabling the selective removal of metabolic waste products from the brain via the cerebral vasculature (Sweeney et al., 2018). For this reason, the BBB is critical for the proper functioning of neural circuits, and thus BBB dysfunction or disruption has been identified as a key component of several neurological conditions (Profaci et al., 2020). To support these functions, a physical barrier is created in the BBB structure via tight junctions between endothelial cells and the outer wall of the endothelium, which are subsequently surrounded by the endfeet of pericytes and astrocytes. Tight junctions ensure paracellular selective permeability to solutes. Tight junction proteins at the BBB include occludin, zonulin, junctional adhesion molecules, and claudins, with claudin-5 being the most expressed claudin in the cerebral vasculature (Profaci et al., 2020). Although endothelial cells primarily control the integrity and function of the BBB, other components of the neurovascular unit (eg, pericytes, glia and neurons) also play important roles in maintaining normal BBB function.
[0057] The BSCB and the BBB share the same specialized system, composed of non-fenestrated endothelial cells and their accessory structures, including the basement membrane, pericytes and astrocytes (Bartanusz et al., 2011). However, the BSCB differs from the BBB in terms of the levels of specific tight and adherens junction proteins, glycogen deposits and transporter molecules, and the BSCB is more permeable than the BBB (Bartanusz et al., 2011).
[0058] The BCSFB plays a major role in (1) preventing blood-borne pathogenic components from entering the CSF and (2) ensuring the excretion of waste products (Liddelow, 2015). The BCSFB is formed by different types of cell junctions between epithelial cells of the choroid plexus of the ventricles (Solar et al., 2020). The tight junction protein family of the BCSF includes occludin, zonulin, junctional adhesion molecules, and claudins, similar to those present in the BBB (Solar et al., 2020).
[0059] Barrier pathologies have been implicated in several neurodegenerative diseases (e.g., AD, ALS, PD, HD) ( Kakaroubas et al., 2019 ; Yamazaki et al., 2019 ; Sweeney et al., 2018 ; Meister et al., 2015 ; Bartanusz et al., 2011 ), neurovascular diseases (e.g., ischemic stroke, AD) ( Abdullahi et al., 2018 ; Lv et al., 2018 ), CNS injuries (e.g., SCI, TBI) ( Cash and Theus, 2020 ; van Vliet et al., 2020 ; Evran et al., 2020 ; Bartanusz et al., 2011 ), psychiatric disorders (e.g., schizophrenia) ( Greene et al., 2018 ), and autoimmune diseases (e.g., multiple sclerosis) ( Berghoff et al., 2017 ; It is recognized as a major contributing factor in the pathogenesis and progression of retinal diseases (e.g., macular degeneration, diabetic macular edema) (Arima et al., 2020; Hudson et al., 2019; van der Wijk et al., 2019), epilepsy (Profaci et al., 2020), neuropathic pain (Bartanusz et al., 2011), and other conditions (e.g., SARS-Cov2 infection and aging) (Pellegrini et al., 2020; Buzhdygan et al., 2020).
[0060] Barrier pathology is recognized as a risk factor for many diseases or disorders, such as those listed herein. A "risk factor" can be considered to be a barrier defect or alteration or dysfunction that may be the origin of a disease and contribute to the maintenance of favorable conditions for the development, maintenance or progression of the disease, and therefore restoration of a normal or fully functional barrier (fully functional, or incompletely functional enough to have a barrier effect) is itself a therapeutic objective. It can also be considered that a barrier defect or alteration or dysfunction may be one of the causative factors or exacerbating factors of a disease and contribute to the maintenance of favorable conditions for the maintenance or progression of the disease, and therefore restoration of a normal or fully functional barrier (fully functional, or incompletely functional enough to have a barrier effect) is itself a therapeutic objective.
[0061] These therapeutic objectives are achieved by some or all of the technical effects that result from administering the peptides of the present invention to a subject in need of barrier restoration or protection, which technical effects can be realized by comparison with untreated subjects.
[0062] The technical effect is a reduction in barrier permeability, or pathological barrier permeability, or restoration or improvement of normal barrier permeability, relative to the condition without treatment. Such an effect is demonstrated in the examples by an increase in electrical resistance TEER, an increase in claudin-5 expression, an increase in occludin expression, and a decrease in permeability to dextran and sucrose. In vivo, the achievement of the technical effect can be demonstrated in treated subjects using at least two marker measurements, in particular any one or any combination of the following: Ktrans measured using available methods, such as that disclosed in Montagne et al., 2020, e.g., Ktrans in the hippocampus is 1.6×10 -3 min -1 Less than 1.5, 1.4, or 1.3 x 10 -3 min -1Less than 1.2 × 10 -3 min -1 ) and / or K trans in the substantia nigra (SN): 0.4 or 0.35×10 -3 min -1 or normal subjects (approximately 0.3 × 10 -3 min -1 ), K trans in the posterior cortex (PC): 0.5 or 0.45 × 10 -3 min -1 or normal subjects (approximately 0.4 × 10 -3 min -1 ), Albumin index (Qalb), measured using available methods such as those disclosed in Uher et al., 2015, is less than 6.5, 5, or 4 if the subject is under 40 years of age, or less than 8, 7, or 6 if the subject is over 40 years of age; As mentioned in Castellazzi et al., 2020, QAlb is less than 6.5, 5 or 4 if the subject is 15-40 years of age, QAlb is less than 8, 7 or 6 if the subject is 41-60 years of age, and QAlb is less than 9, 8 or 7 if the subject is over 60 years of age.
[0063] The technical effect is the restoration or improvement of endothelial and / or epithelial tight junctions of the biological barrier, as demonstrated in the examples by an increase in electrical resistance TEER, an increase in Claudin-5 expression, an increase in occludin expression, and a decrease in permeability to dextran and sucrose. In vivo, the achievement of the technical effect in a subject can be demonstrated using the same marker levels as described for barrier permeability, using at least two marker measurements, in particular either one or any combination of Ktrans and / or Qalb.
[0064] These previously undisclosed technical effects and their impact on marker variation contribute to the effectiveness of the peptides in treating barrier dysfunction and to the proposition of using the peptides for therapeutically treating biological barrier dysfunction in a subject with the aim of reducing the risk of biological barrier dysfunction, of the appearance or progression of such dysfunction, of sudden appearance of disease, of chronicity of disease, or of unfavourable disease progression.
[0065] SCO-spondin derived peptides for use in the uses and methods disclosed herein: "SCO-spondin" is a glycoprotein specific to the central nervous system and is present in all vertebrates from chordates to humans. SCO-spondin is known as a molecule of the extracellular matrix secreted by the subcommissural organ, a specific organ located at the top of the third ventricle. SCO-spondin is a molecule of large size. SCO-spondin consists of more than 4,500 amino acids and has a multimodular structure containing various conserved protein patterns, including 26 types of TR or TSR patterns. Certain peptides derived from SCO-spondin that start with the TSR pattern are known to have biological activity in nerves or nerve cells (described in particular in WO-99 / 03890).
[0066] The "TSR or TR pattern" is a protein domain of approximately 55-60 residues, based on the alignment of the conserved amino acids cysteine, tryptophan and arginine. These patterns were first isolated in TSP-1 (thrombospondin 1), a molecule that mediates coagulation. They were subsequently described in a number of other molecules, such as SCO-spondin. In fact, this thrombospondin type 1 unit (TSR) contains about 55-60 amino acids (AA), some of which, such as cysteine (C), tryptophan (W), serine (S), glycine (G), arginine (R) and proline (P), are highly conserved in all proteins studied so far and previously mentioned.
[0067] SCO-spondin peptides or peptide compounds are used in the practice of the present invention (for various purposes of the invention, i.e. peptides or compositions for use, methods of use, methods of treatment, use of peptides for the manufacture of medicaments, etc.). Pharmaceutical compositions comprising at least one of the peptides according to the present invention and a pharma-ceutically acceptable vehicle, carrier or diluent are also used.
[0068] In particular, the present invention relates to a compound having the sequence X1-WS-A1-WS-A2-CS-A3-A4-CG-X2 (SEQ ID NO: 1) A peptide of the formula: During the ceremony, A1, A2, A3 and A4 each have an amino acid sequence of 1 to 5 amino acids, in which two cysteines may or may not form a disulfide bridge; X1 and X2 each consist of an amino acid sequence consisting of 1 to 6 amino acids, or X1 and X2 are absent; The N-terminal amino acid can be acetylated (e.g., carrying HCCOHN-), the C-terminal amino acid can be amidated (e.g., carrying -CONH), or the N-terminal amino acid can be acetylated and the C-terminal amino acid can be amidated. Use peptides.
[0069] In one embodiment, in the formula of SEQ ID NO: 1, X1 or X2, or both X1 and X2 are absent. In one embodiment, when X1 and / or X2 are absent, the N-terminus W is acetylated and / or the C-terminus G is amidated. Preferably, both X1 and X2 are absent, the N-terminus W is acetylated and the C-terminus G is amidated.
[0070] In particular, the present invention relates to a compound having the sequence WS-A1-WS-A2-CS-A3-A4-CG (SEQ ID NO: 2) A peptide of the formula: During the ceremony, A1, A2, A3 and A4 each have an amino acid sequence of 1 to 5 amino acids, and two cysteines may or may not form a disulfide bridge; Use peptides.
[0071] In one embodiment of the formulas of SEQ ID NO: 1 and 2, the peptide is a linear peptide or the cysteines appearing in the peptide formulas of SEQ ID NO: 1 and 2 do not form disulfide bridges (reduced form).
[0072] In a preferred embodiment, the two cysteines occurring in the peptide formulas of SEQ ID NOs: 1 and 2 form a disulfide bridge (oxidized form).
[0073] Preferably, in the formulae of SEQ ID NO: 1 and 2, A1, A2, A3 and / or preferably A4 consist of preferably 1 or 2 amino acids, more preferably 1 amino acid.
[0074] Preferably, A1 is selected from G, V, S, P and A, more preferably G and S.
[0075] Preferably, A2 is selected from G, V, S, P and A, more preferably G, S.
[0076] Preferably, A3 is selected from R, A and V, more preferably R, V.
[0077] Preferably, A4 is selected from S, T, P and A, more preferably S, T.
[0078] Preferably, A1 and A2 are independently selected from G and S.
[0079] Preferably, A3-A4 is selected from RS or VS or VT or RT.
[0080] Preferably, X1, X2, A1, A2, A3 and A4 do not contain cysteine.
[0081] When X1 is an amino acid sequence of 1 to 6 amino acids, the amino acids may be any amino acid, and are preferably selected from V, L, A, P, and any combination thereof.
[0082] When X2 is an amino acid sequence of 1 to 6 amino acids, the amino acids may be any amino acids, preferably selected from L, G, I, F, and any combination thereof.
[0083] In one embodiment, the peptide of SEQ ID NO: 1 or 2 is such that A1 and A2 are independently selected from G and S, and A3-A4 are selected from RS or VS or VT or RT.
[0084] In a detailed manner, the peptide is further acetylated and / or amidated. In one embodiment, the peptide is a linear peptide or the cysteines do not form disulfide bridges. In another embodiment, the peptide has two cysteines that form disulfide bridges (C-terminal cyclization). In another embodiment, the peptide used in the present invention or administered to a patient includes both oxidized and linear peptide forms.
[0085] For the purposes of the present invention, the term "amino acid" refers to both natural and non-natural amino acids, and amino acid changes, including natural to non-natural, can be routinely made by those skilled in the art while maintaining the function or efficacy of the original peptide. "Natural amino acids" refers to the L-form amino acids that can be found in natural proteins, namely alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. "Non-natural amino acids" refers to the preceding amino acids in the D-form, as well as the homoforms of certain amino acids, such as arginine, lysine, phenylalanine and serine, or the nor-forms of leucine or valine. Other amino acids, such as α-aminobutyric acid, agmatine, α-aminoisobutyric acid, sarcosine, statine, ornithine, deaminotyrosine, etc., are also included in this definition. The nomenclature used to describe peptide sequences is the International Nomenclature using a one-letter code with the amino terminus shown on the left and the carboxy terminus shown on the right. A dash "-" represents the common peptide bond linking the amino acids of the sequence.
[0086] In one embodiment, a peptide according to the present invention, for example any one of the peptides of the sequences of SEQ ID NOs: 1 to 63, comprises N-terminal acetylation, C-terminal amidation, or both N-terminal acetylation and C-terminal amidation.
[0087] In various embodiments, the present invention relates to the use of a polypeptide consisting essentially of or consisting of the following amino acid sequences (Table A):
[0088] [Table 1A]
[0089] [Table 1B]
[0090] In one embodiment, the peptides of the sequences SEQ ID NO: 3 to 34 disclosed in Table A are linear peptides or the cysteines do not form disulfide bridges (reduced peptides). In another embodiment, the peptides of the sequences SEQ ID NO: 3 to 34 disclosed in Table A supra have two cysteines that are oxidized to form disulfide bridges (oxidized peptides). In another embodiment, the peptides used in the invention or administered to a patient comprise both oxidized and linear peptide forms of the same peptide sequence. In yet another embodiment, the peptides used in the invention or administered to a patient comprise a mixture of at least two of these different peptides selected from the sequences SEQ ID NO: 3 to 34, which mixture may be, for example, a mixture of at least two linear peptides or a mixture of at least two oxidized peptides or a mixture of at least one linear peptide and at least one oxidized peptide, having the same amino acid sequence.
[0091] In a preferred embodiment, the peptide consists of the amino acid sequence WSGWSSCSRSCG (SEQ ID NO: 3). In one embodiment, the peptide is a linear peptide or the cysteines do not form disulfide bridges (reduced form, called NX210). In another embodiment, the peptide has two cysteines that are oxidized to form disulfide bridges (oxidized form), called NX218. In another embodiment, the peptide used in the invention or administered to a patient includes both oxidized and reduced forms.
[0092] In one embodiment of the peptide of SEQ ID NO:1, - X1 represents a hydrogen atom or P or AP or LAP or VLAP, and / or - X2 represents a hydrogen atom or L, LG, LGL, LGLI or LGLIF.
[0093] In various embodiments, the present invention therefore relates to the use of a polypeptide consisting or consisting essentially of the following amino acid sequence (Table B):
[0094] [Table 2]
[0095] In one embodiment, the peptides of sequences SEQ ID NO: 35-63 disclosed in Table B or sequences SEQ ID NO: 3-63 disclosed in Table A+Table B are linear peptides or the cysteines do not form disulfide bridges (reduced peptides). In another embodiment, the peptides have two cysteines that are oxidized to form disulfide bridges (oxidized peptides). In another embodiment, the peptides used in the invention or administered to a patient comprise both oxidized and linear peptide forms of the same peptide sequence. In yet another embodiment, the peptides used in the invention or administered to a patient comprise a mixture of at least two of these different peptides selected from sequences SEQ ID NO: 35-63 or 3-63, which mixture may be, for example, a mixture of at least two linear peptides or a mixture of at least two oxidized peptides or a mixture of at least one linear peptide and at least one oxidized peptide, having the same amino acid sequence.
[0096] Each of the peptides of the sequences of SEQ ID NOs: 3 to 63 can be acetylated, amidated, or acetylated and amidated.
[0097] The peptides used in the present invention or administered to a patient are defined by their amino acid sequence. The peptides used can be one peptide disclosed herein or a mixture of at least two peptides disclosed herein. The mixture also encompasses mixtures of linear and oxidized peptides of the same or different amino acid sequences. According to the present invention, when 100% pure peptides can be used, the peptides can have a purity of more than 80%, preferably 85%, more preferably 90%, even more preferably 95, 96, 97, 98, or 99% or more, and the present invention encompasses them. Conventional purification methods, for example by chromatography, can be used to purify the desired peptide compound.
[0098] In one embodiment, the peptides used in the present invention or administered to a patient contain both oxidized peptide (Op) and linear peptide (Lp) forms, for example in comparable or not comparable amounts, for example (in % by number) Op: 10, 20, 25, 30, 40, 50, 60, 70, 80 or 90%, the remainder to make 100% being Lp. The oxidized and linear peptides combined may be of the same sequence or of different sequences. For example, the oxidized and linear forms of the peptide of sequence SEQ ID NO: 3 are so combined, for example in the ratios disclosed above (NX210 and NX218). The same applies for any one of the peptides of sequences SEQ ID NO: 4 to 34 and 35 to 63.
[0099] Pharmaceutical Compositions: As used herein, a pharmaceutical composition comprises as an active ingredient the aforementioned peptides, or mixtures of peptides, e.g., peptides of different amino acid composition, or mixtures of peptides of the same amino acid composition in their oxidized and linear forms, together with one or more pharma- ceutically acceptable vehicles, carriers or excipients.
[0100] The peptide compounds according to the invention can be used in a pharmaceutical composition or in the manufacture of a medicament for preventing or treating any one of the bodily dysfunctions disclosed herein, such as biobarrier dysfunction and / or altered tight junctions.
[0101] In a first embodiment, the dysfunction is detected by measuring the level of soluble PDGFRβ in the CSF.
[0102] In another embodiment, the functional impairment is detected by measuring the ratio of CSF albumin levels to serum albumin levels.
[0103] In another embodiment, dysfunction is detected by measuring the local BBB permeability constant, Ktrans, for the contrast agent gadolinium, identified by DCE-MRI.
[0104] In another embodiment, the dysfunction is detected by measuring hypointensities identified by T2* MRI or SWI MRI.
[0105] In another embodiment, the impairment is detected by measuring regional brain uptake of 2-deoxyglucose using FDG-PET.
[0106] In another embodiment, the functional impairment is detected by measuring the albumin index (Qalb), which is the ratio of CSF albumin level to serum albumin level.
[0107] In these compositions or medicaments, the active ingredient can be incorporated into the composition in various forms, i.e. in the form of a solution, generally an aqueous solution, or in lyophilized form, or in the form of an emulsion, or in any other pharma- ceutically and physiologically acceptable form suitable for the route of administration.
[0108] The route of administration may be a systemic route. In particular, the following injection or administration routes may be mentioned: intravenous, intrathecal, intraperitoneal, intranasal, subcutaneous, intramuscular, sublingual, oral, and combinations thereof.
[0109] Administration may be local, especially using intracerebral routes, especially intraventricular administration.
[0110] Compositions containing one or more of the peptides disclosed herein are sterile. These compositions are suitable for administration leading to delivery of peptides to a patient, for example, into the blood circulation. Delivery to a patient is delivery of a sufficient amount of peptide, which is correlated with a beneficial effect. "Pharmacological effect" can include beneficial effects on one or more of BBB, tight junction, claudin-5 expression level, claudin-5 distribution, occludin expression level, transendothelial and / or transepithelial electrical resistance, dysregulation of transcompartmental permeability of specific compounds or molecules, Qalb, Ktrans, as disclosed herein.
[0111] In some embodiments, the active ingredient in the pharmaceutical composition consists of (1) a linear peptide disclosed herein, (2) an oxidized peptide disclosed herein, (3) NX210, (4) NX218, or (5) a mixture of linear and oxidized peptides, particularly NX210 and NX218, in similar or dissimilar amounts, as disclosed above.
[0112] The active ingredient can be administered to animals and humans in unit dosage forms in admixture with conventional pharmaceutical supports, carriers, excipients or vehicles.Suitable unit dosage forms include oral route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal dosage forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subcutaneous, transdermal and intranasal dosage forms and rectal dosage forms.
[0113] Preferably, the pharmaceutical compositions contain pharma- ceutically acceptable carriers, excipients or vehicles for administration, e.g., liquid preparations that can be injected into a patient, e.g., to deliver the active ingredient into the bloodstream. These may in particular be ready-to-use solutions, e.g., isotonic, sterile saline (monosodium or disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride, etc., or mixtures of such salts), or dry, in particular lyophilized, compositions that can be made up into administrable solutions by addition of sterile water or saline, as the case may be.
[0114] Pharmaceutical forms include sterile aqueous solutions or dispersions, formulations including sesame oil, peanut oil or aqueous propylene glycol, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
[0115] Sterile injectable solutions are prepared by incorporating the active polypeptide in the required amount in the appropriate solvent, followed by filtered sterilization.
[0116] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation, and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, although drug release capsules and the like can also be used.
[0117] For suitable administration in aqueous solution, for example, the solution should be suitably buffered if necessary, and liquid diluent is first made isotonic with sufficient saline or glucose.These particular aqueous solutions are particularly suitable for, for example, intravenous, intramuscular, subcutaneous, and intraperitoneal administration.In this regard, the sterile aqueous medium that can be used will be known to those skilled in the art in light of this disclosure.In addition to the compound of the present invention formulated for injection administration, such as intravenous or intramuscular injection, other pharmacologic acceptable forms include, for example, tablets or other solids for oral administration, liposomal formulations, sustained release capsules, and any other form that currently is used to deliver active ingredient.
[0118] A dose of peptide, expressed as the mass of peptide per kg of patient body weight, may range from about 1 μg / kg to about 1 g / kg, particularly from about 10 μg / kg to about 100 mg / kg, for example from about 50 μg / kg to about 50 mg / kg.
[0119] The dosing regimen may include a single dose or multiple doses. According to one embodiment, multiple doses may include administering one dose per treatment day, for example, every day or every 2 or 3 days, for the treatment period. According to another embodiment, multiple doses may include administering at least two doses per treatment day, for example, two, three or more doses per day, for the treatment period. In these embodiments, the treatment period may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45 or more days (for example, up to 6 months). The treatment is designed so that the patient maintains a "benefit" from the treatment over a "period". The "benefit" may include the "pharmaceutical effect" described above, i.e., the peptide is beneficial to a subject suffering from or at risk of suffering from one of these diseases. Thus, the peptides allow the improvement (increase, restoration or protection) of the tight junctions of epithelial and / or endothelial cells involved in the biological barrier, of the paracellular permeability at the level of these cells or barriers, of the expression level of claudin-5, of the distribution of claudin-5 (increasing the level of claudin-5 at the surface of barrier endothelial cells and / or epithelial cells, in particular they allow claudin-5 present in vesicles to reach or diffuse to the surface of the barrier endothelial cells and / or epithelial cell membrane), of the expression level of occludin, and therefore of the functional biological barriers such as the BBB, and of the associated diseases. This "duration" may depend on the dosing regimen and on the patient himself, for example on the severity of the disease and the responsiveness of the patient to the dose of the regimen. "Improvement" includes "partial improvement" and "complete improvement". It is said to be "partial" when a partial restoration of the integrity of the biological barrier or the integrity of the tight junctions and their physiological functions is observed in the subject, and with respect to the initial state of the subject before treatment, these significant improvements are observed but remain significantly lower than in healthy subjects. "Complete recovery" means that the subject has restored biological barrier integrity or tight junction integrity and their physiological functions or that they are not significantly different from healthy subjects.As explained, barrier integrity or restoration thereof can be assessed using the methods disclosed herein.
[0120] The administration regimen may be adapted to the severity of barrier dysfunction. For mild severity, the regimen may include administration every 3 days. For moderate severity, the regimen may include administration every 2 days. For severe severity, the regimen may include daily administration.
[0121] In the absence of diseases or conditions known to be associated with biological barrier dysfunction, the regimen can be every 3 days or every 2 days.
[0122] Further definitions, features and aspects of the present invention: The administration or use of a "peptide" or "peptides" or "peptide(s)" is a generic term and the present invention covers the administration or use of one individual peptide or multiple individual peptides, i.e. at least two peptides according to the present disclosure. Thus, in the present disclosure, the singular or plural is not limiting, unless otherwise indicated, and each time covers one individual peptide or at least two peptides. The same is true for the equivalent term "peptide compound", which can be used interchangeably with "peptide".
[0123] "Treating", "treated" or "treating" refers to the delivery of a quantity of a peptide compound according to the invention to a subject. As used herein, these terms refer to therapeutic agents aimed at delaying (alleviating) an undesirable physiological condition, disorder or disease, or obtaining a beneficial or desired clinical outcome. For purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, modulating, stabilizing, correcting a bodily dysfunction, such as a biological barrier dysfunction or tight junction dysfunction, and may include modulating, stabilizing, correcting, increasing, decreasing one or more markers associated therewith, such as the level or distribution of claudin-5, occludin levels, Ktrans, Qalb, etc. For purposes of the present invention, beneficial or desired clinical outcomes also include stabilization (i.e., not worsening) of a symptom, condition, disorder or disease state, delay in the onset or progression of a symptom, condition, disorder or disease, amelioration of a symptom, condition, disorder or disease state, and remission (whether partial or complete) with substantial restoration of normal function, or improvement or amelioration of a condition, disorder or disease. The terms "treating," "treated," or "treating" may include preventing, suppressing, inhibiting, ameliorating, or completely eliminating a physical dysfunction or a symptom that may be associated therewith. Preventing a disease may involve administering a composition of the invention to a subject prior to the onset of a physical dysfunction or a symptom associated therewith. Suppressing these disease symptoms may involve administering a composition of the invention to a subject after induction of the disease but prior to its clinical appearance. Suppressing or ameliorating these disease symptoms may involve administering a composition of the invention to a subject after the clinical appearance of these disease symptoms.
[0124] Similar terms such as "effective amount", "sufficient amount" and "therapeutically effective amount" are used interchangeably herein, unless otherwise defined, to refer to an amount of one or more peptides of the present invention effective for a period of time necessary to achieve a desired therapeutic result. An effective dosage can be determined by one of skill in the art and can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to elicit a desired response in the individual. As used herein, the term can also refer to an amount effective to produce a desired in vivo effect in a subject, particularly stabilization or restoration of a biological barrier. A therapeutically effective amount can be administered in one or more administrations (e.g., the composition can be given as a preventative treatment or therapeutically, at any stage of disease progression, before or after symptoms, etc.), applications, or dosages, and is not intended to be limited to a particular formulation, combination, or route of administration. It is within the scope of this disclosure that the peptides can be administered at various times during the course of treatment of a subject. The administration time and dosage used will depend on several factors, such as the goal of the treatment (e.g., whether treatment or prevention), the condition of the subject, and can be readily determined by one of skill in the art. A therapeutically effective amount is also an amount in which any toxic or harmful effects of a substance are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective at the dosage and for the period of time necessary to achieve the desired prophylactic result. Typically, a prophylactic dose is used in subjects before or at an early stage of disease, so that the prophylactically effective amount may be less than the therapeutically effective amount. An "effective amount", a "sufficient amount" can also take into account the combination of different peptides when considering the amount of peptide separately and / or when considering the combination with another active ingredient, for example, the dose of one or two drugs in the combination can be reduced as a result of the combined effect or synergistic effect.
[0125] The terms "comprise(s)", "include(s)", "having", "has", "can", "contain(s)", and variations thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not exclude the possibility of further actions or products, e.g., peptides, compounds, or drugs. The singular forms "a", "and", and "the" include plural references unless the context clearly indicates otherwise. The present disclosure also contemplates other embodiments that "comprise", "consist of", and "consist essentially of" the embodiments or elements presented herein, whether or not expressly stated.
[0126] "Patient or subject" means an animal, particularly a mammal, including a human. In one embodiment, the subject is a human. In other embodiments, the subject is a large or livestock animal, a companion animal (e.g., cat, dog), or a sport animal (e.g., horse).
[0127] In one embodiment of the use or method of treatment of the present invention, one or more of the following diseases may be excluded: Parkinson's disease (PD), multiple sclerosis (MS), myopathy, non-nervous system injury such as spinal cord injury (SCI) or optic nerve injury (ONI), tauopathy (i.e. tau-positive neurodegenerative diseases including any of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), tau-positive frontotemporal dementia such as Pick's disease, dementia with Lewy bodies, corticobasal degeneration, Niemann-Pick disease type C, chronic traumatic encephalopathy including dementia pugilistica, postencephalitic parkinsonism). The following may be individually excluded: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), tau-positive frontotemporal dementias such as Pick's disease, dementia with Lewy bodies, corticobasal degeneration, Niemann-Pick disease type C, chronic traumatic encephalopathy including dementia pugilistica, post-encephalitic parkinsonism, cerebral ischemia, CNS neurotraumatic (i.e. spinal cord or brain injury) conditions, viral neurodegeneration, amyotrophic lateral sclerosis, spinal muscular atrophy, Huntington's disease, prion diseases, PSP, multiple system atrophy, adrenoleukodystrophy, Down's syndrome.
[0128] The invention will now be explained in more detail, by way of non-limiting examples, with reference to the drawings, in which: [Brief description of the drawings]
[0129] [Figure 1] NX218 dose-dependently increases the transendothelial electrical resistance of mouse brain endothelial cell monolayers in vitro. Transendothelial electrical resistance (TEER) of mouse brain endothelial bEnd.3 cells grown on Transwell inserts was measured after exposure to vehicle or various doses of NX218 (1, 10, 100 μM) for 24 h (A), 48 h (B), or 72 h (C). One-way ANOVA followed by Dunnett's multiple comparison test: ***p<0.0001, **p<0.001, *p<0.05 compared to control group, n=6 / group (A) and n=9 / group (B, C). [Diagram 2] NX218 dose-dependently reduces the permeability of mouse brain endothelial cell monolayers in vitro. The permeability of mouse brain endothelial bEnd.3 cells grown on Transwell inserts to FITC-40kDa dextran was measured after exposure to vehicle or various doses of NX218 (1, 10, 100 μM) for 24 h (A), 48 h (B), or 72 h (C). One-way ANOVA followed by Dunnett's multiple comparison test: **p<0.001 compared to control, *p<0.05, n=3 / group. [Diagram 3]Treatment with NX218 for 24 h increases the expression of claudin-5 at tight junctions in mouse brain endothelial cell cultures. Mouse brain endothelial bEnd.3 cells were fixed and stained for claudin-5 after exposure to vehicle or various doses of NX218 (1, 10, 100 μM) for 24 h (A), 48 h (B), or 72 h (C). Claudin-5 immunoreactivity at membrane localization was finally quantified to assess claudin-5 protein levels at tight junctions. One-way ANOVA followed by Dunnett's multiple comparison test: ***p<0.0001, *p<0.05, n=6 / group (A, B) and n=4 / group (C) compared with control group. Representative photomicrographs of endothelial cells immunostained for claudin-5 (red) (D, scale bar: 50 μm). [Figure 4] NX218 dose-dependently reduces the permeability of primary rat choroid plexus epithelial cell monolayers in vitro. The permeability of primary rat choroid plexus epithelial cells grown on Transwell inserts to [14C]-sucrose was measured after 2 h exposure (0–90 min) to vehicle or various doses of NX218 (192, 768 μM) (A). One-way ANOVA followed by Dunnett's multiple comparison test: ***p<0.0001 compared to control, *p<0.05, n=4 / group. [Diagram 5] Treatment with NX218 for 72 hours increases the expression of claudin-5 at tight junctions in mouse brain endothelial cell cultures. Mouse brain endothelial bEnd.3 cells were exposed to vehicle or various doses of NX218 (1, 10, 100 μM) for 72 hours and then fixed and stained for claudin-5. Claudin-5 immunoreactivity at membrane localization was finally quantified to assess claudin-5 protein levels at tight junctions. One-way ANOVA followed by Dunnett's multiple comparison test: *p<0.05 compared to control, n=5. [Figure 6]Treatment with NX218 for 24 hours increases the expression of occludin in mouse brain endothelial cell cultures. Mouse brain endothelial bEnd.3 cells were exposed to vehicle or various doses of NX218 (1, 10, 100 μM) for 24 hours, and cell layers were harvested and Western blotted to quantify occludin protein levels. One-way ANOVA followed by Dunnett's multiple comparison test: **p<0.01, *p<0.05, n=8 compared to control group (A). Corresponding representative Western blot for occludin (B). Example 1
[0130] Synthesis of NX peptide The process for the manufacture of any of the peptides of sequences SEQ ID NO: 1, 2 or sequences 3-63, particularly the peptide used in the Examples section, for example NX210 (SEQ ID NO: 3), is based on solid-phase peptide synthesis applying N-α-Fmoc (side chain) protected amino acids as building blocks in the construction of the peptide. The protocol used consists of coupling of the C-terminal glycine on MBHA resin with an N-α-Fmoc protected amino acid attached to an MPPA linker followed by a sequence of Fmoc coupling / deprotection. After construction of the peptide on the resin, a step is carried out in which the peptide is simultaneously cleaved from the resin and the amino acid side chains are deprotected.
[0131] The crude peptide is precipitated, filtered and dried. Prior to purification by preparative reverse phase chromatography, the peptide is dissolved in an aqueous solution containing acetonitrile. The purified peptide in solution is concentrated, followed by an ion exchange step to obtain the peptide in its acetate form.
[0132] For synthetic details, those skilled in the art can refer to U.S. Pat. No. 6,995,140 and WO2018146283, and for oxidized forms of the peptides disclosed herein, WO 2017 / 051135, all of which are incorporated herein by reference.
[0133] Those skilled in the art can further utilize standard methods for producing any of the disclosed peptides of the present invention, including peptides modified or protected at the N-terminus and C-terminus. For acetylation and / or amidation of peptides at the N-terminus and C-terminus, respectively, those skilled in the art can refer to standard techniques, such as those described in Biophysical Journal, Vol. 95, November 2008, pp. 4879-4889, which is also incorporated herein by reference. Example 2
[0134] Synthesis of cyclic NX peptide A polypeptide of the sequence WSGWSSCSRSCG was added to human serum albumin (HSA) in a 1:1 ratio and incubated for 1-3 hours with stirring in air at room temperature. By using HPLC, the inventors observed the formation of a peak corresponding to the polypeptide sequence WSGWSSCSRSCG in which two cysteines are linked by a disulfide bridge. After removing the albumin by precipitation, the product was subsequently purified and analyzed by HPLC. Knowing that the smaller the amount of albumin, the easier it is to eliminate, by using different ratios of albumin and the polypeptide corresponding to the sequence WSGWSSCSRSCG, it is possible to influence the cyclization rate and the final yield of cyclization. The cyclization compound is NX218.
[0135] Those skilled in the art can refer to WO 2017051135 for further synthetic details, which is incorporated herein by reference. Example 3
[0136] Effect of NX218 on transendothelial electrical resistance of mouse brain endothelial cell monolayers. According to Greene et al., 2019, strengthening of tight junctions results in high electrical resistance. This experiment aims to demonstrate the effect of peptides on electrical resistance.
[0137] To determine the effect of NX218 on the transendothelial electrical resistance (TEER) of mouse brain endothelial cells, cells were grown in the presence or absence of NX218 on a semi-permeable membrane inserted into a culture well, and TEER was recorded using electrodes placed on either side of the membrane and a resistance meter.
[0138] Cell culture: Mouse brain endothelial cells (bEnd.3, American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM sodium pyruvate at 37°C in a 5% CO2 incubator.
[0139] TEER Measurement: bEnd.3 cells were grown on 6.5 mm diameter, 0.4 μm pore size polyester membrane HTS Transwell inserts (5 × 10 cells per well). 4 (100 x 100 cells, containing 200 μL and 800 μL of culture medium in the apical and basolateral compartments, respectively). Three days after seeding, cells were treated with vehicle or NX218 (1, 10 and 100 μM) for 1, 2 or 3 days. TEER values were measured using an EVOM ohmmeter equipped with "chopstick" electrodes. One electrode was placed in the apical chamber and the other in the basolateral chamber. Before measurements, the chambers were replaced with fresh medium.
[0140] result: The results are shown in FIG. 1 and Tables 1, 2 and 3 below.
[0141] [Table 3]
[0142] [Table 4]
[0143] [Table 5]
[0144] Conclusion: When endothelial cell monolayers were treated with 10 and 100 μM NX218 for 1, 2 or 3 days, resistance was significantly increased in a dose-dependent manner compared to vehicle-treated endothelial cell monolayers. Example 4
[0145] Effect of NX218 on the permeability of mouse brain endothelial cell monolayers. According to Greene et al., 2019, FITC-dextran allows for monitoring of brain endothelial cell permeability.
[0146] To determine the effect of NX218 on the permeability of mouse brain endothelial cells to 40 kDa FITC-dextran, cells were grown in the presence or absence of NX218 on semi-permeable membranes inserted into culture wells. FITC-dextran was then placed on the apical chamber (containing the cells) and its levels were measured (based on fluorescence) in the basolateral chamber one hour later.
[0147] Cell culture: Mouse brain endothelial cells (bEnd.3, American Type Culture Collection) were cultured in DMEM supplemented with 10% FBS and 2 mM sodium pyruvate at 37° C. in a 5% CO 2 incubator.
[0148] Permeability assay: bEnd.3 cells were grown to confluence (5 × 10 cells per well) on 0.4 μm pore size Corning HTS 24-well Transwell polyester inserts coated with 1% fibronectin. 4Cells, containing 200 μL and 800 μL of medium in the apical and basolateral compartments, respectively, were treated with vehicle or NX218 (1, 10 and 100 μM) for 1, 2 or 3 days. 200 μL of 1 mg / mL 40 kDa FITC-dextran in DMEM supplemented with 10% FBS and 2 mM sodium pyruvate was added to the apical chamber of each well and cells were incubated at 37°C. Sampling aliquots were taken from the basolateral chamber and replaced with fresh medium every 15 min for 1 h and then transferred to a 96-well plate. FITC-dextran fluorescence was determined using a spectrofluorometer at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Relative fluorescence units were converted to nanograms per milliliter using a FITC-dextran standard curve and corrected for background fluorescence and serial dilutions over the course of the experiment. Data are expressed as endothelial permeability coefficient (Pe) in cm / min.
[0149] result: The results are shown in FIG. 2 and Tables 4, 5 and 6 below.
[0150] [Table 6]
[0151] [Table 7]
[0152] [Table 8]
[0153] Conclusion: For endothelial cell monolayers treated with NX218, a strong decrease in permeability to FITC-dextran was observed in a dose-dependent manner, especially after 2 or 3 days of treatment for the highest dose. Example 5
[0154] Effect of NX218 on the expression of claudin-5 at tight junctions in mouse brain endothelial cell cultures To understand the effect of NX218 on the TEER and permeability of mouse brain endothelial cells in Examples 3 and 4, the levels of the tight junction protein claudin-5 were assessed using immunocytochemistry.
[0155] Cell culture: Mouse brain endothelial cells (bEnd.3, American Type Culture Collection) were cultured in DMEM supplemented with 10% fetal FBS and 2 mM sodium pyruvate at 37° C. in a 5% CO 2 incubator.
[0156] Immunocytochemistry: bEnd.3 cells were seeded onto Nunc Lab-Tek II Chamber Slides coated with 1% fibronectin in medium (1 × 10 cells per well in 300 μL). 5 Two days after seeding, cells were treated with vehicle or NX218 (1, 10 and 100 μM) for 1, 2 or 3 days. Cells were then fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min at room temperature (RT), washed twice with PBS, and incubated with 5% normal goat serum and 0.05% Triton X-100 in PBS for 1 h at RT, followed by incubation with polyclonal rabbit anti-claudin-5 (1 / 100, 34-1600, Invitrogen) overnight at 4°C. Cells were then washed three times with PBS, incubated with goat anti-rabbit Cy3 secondary antibody (1 / 500, ab6939, Abcam) for 2 h at RT, and counterstained with Hoechst 33258 to visualize nuclei. Slides were removed from the chambers and mounted with Aqua Poly / Mount before visualization by confocal laser scanning / microscopy. Finally, claudin-5 protein levels were assessed by quantifying claudin-5 immunoreactivity (intensity) at membrane localization. Data are expressed as a percentage of control conditions.
[0157] result: The results are shown in FIG. 3 and Tables 7, 8 and 9 below.
[0158] [Table 9]
[0159] [Table 10]
[0160] [Table 11]
[0161] Conclusion: A significant increase in claudin-5 levels was observed when endothelial cell monolayers were treated with 10 and 100 μM NX218 for 24 h, although levels after 2 or 3 days of treatment were similar between control and NX218 conditions. Thus, the increased claudin-5 levels induced by NX218 may contribute to the increased TEER and decreased permeability observed in mouse endothelial brain cells in the presence of NX218. Example 6
[0162] Effect of NX218 on the permeability of primary rat choroid plexus epithelial cell monolayers. [ 14 Permeability to [C]-sucrose is a model for assessing BBB permeability ( Greene et al., 2019 ).
[0163] To determine the effect of NX218 on the permeability of primary rat choroid plexus epithelial cell monolayers to radiolabeled sucrose, cells were grown in the presence or absence of NX218 on semipermeable membranes inserted into culture wells. 14C]-sucrose was placed onto the apical chamber (containing the cells) and quantified in the basolateral chamber up to 2 h later.
[0164] Choroid plexus epithelial cells (CPECs) were prepared from lateral ventricular choroid plexus isolated from rats and cultured as previously described (Strazielle et al., 1999). Cells were plated on polycarbonate membranes (pore size 0.4 μm, growth area 0.33 cm). 2 ), exposed to NX218 (0, 250, and 1000 μg / mL) on the membrane facing the blood and labeled for sucrose for 2 h at 37° C. Aliquots were repeatedly sampled from the acceptor compartment (after 12, 25, 40, 60, 90, and 120 min).
[0165] result: The results are shown in FIG. 4, Table 10 and Table 11.
[0166] [Table 12]
[0167] [Table 13]
[0168] Conclusion: In epithelial cell monolayers treated with the highest dose of NX218 (768 μM), as early as 1 h 30 min after treatment, 14 A strong decrease in permeability to [C]-sucrose was observed. Example 7
[0169] Effect of NX218 on the expression of claudin-5 at tight junctions in mouse brain endothelial cell cultures at 72 hours A second independent experiment was performed using the protocol described in Example 5. Pooling of data from two experiments (first experiment in triplicate, second experiment in duplicate, n=5) increased statistical power and allowed the trends observed at 72 hours to reach statistical significance.
[0170] result: The results are shown in Figure 5 and Table 12 below.
[0171] [Table 14]
[0172] Conclusion: When endothelial cell monolayers were treated with 100 μM NX218, the increased levels of claudin-5 were maintained for at least 72 h. Example 8
[0173] Effect of NX218 on the expression of occludin in mouse brain endothelial cell cultures To understand the effect of NX218 on the TEER and permeability of mouse brain endothelial cells, the levels of the tight junction protein occludin were assessed using Western blot.
[0174] Cell culture: Mouse brain endothelial cells (bEnd.3, American Type Culture Collection) were cultured in DMEM supplemented with 10% fetal FBS and 2 mM sodium pyruvate at 37° C. in a 5% CO 2 incubator.
[0175] Western blot For Western blot analysis, bEnd.3 cells were seeded onto 12-well plates (2.5 × 10 cells per well in 1,000 μL). 5Two days after seeding, cells were treated with vehicle or NX218 (1, 10 and 100 μM) for 24 hours. Proteins were isolated from the cell layer using lysis buffer (62.5 mM Tris, 2% SDS, 10 mM dithiothreitol, 10 μL protease inhibitor cocktail / 100 mL (Sigma-Aldrich)), centrifuged at 12,000 rpm for 20 min at 4°C, and the supernatant was used for analysis of tight junction proteins. Protein concentrations were determined by Pierce BCA Protein Assay (Thermo Scientific). 10 μL of samples and standards (working range = 125-2000 μg / mL) were loaded in duplicate into a 96-well plate, and 200 μL of working reagent (BCA Reagent A and BCA Reagent B in a 50:1 ratio) was added to each well, mixed on a shaker, and incubated at 37°C for 30 min. Plates were cooled to room temperature and absorbance was read at 562 nm. Protein concentrations were calculated from standard curves. 10 μg total protein was loaded per well for separation by SDS-polyacrylamide gel electrophoresis (12% acrylamide). Gels were transferred onto methanol-activated polyvinylidene difluoride membranes (Merck Millipore) via semi-dry transfer. Transferred membranes were reactivated with methanol and blocked for 1 h at room temperature with gentle agitation in tris-buffered saline (TBS)-Tween-20 containing 3% w / v Marvel nonfat dry milk. Blocked membranes were washed three times with TBS-Tween-20 and treated overnight at 4°C with primary rabbit polyclonal antibody against occludin (Novus Biotech, ref. NBP1-87402, 65 kDa, 1 / 1000 dilution). The membrane was washed three times for 5 min in TBS-Tween-20 and incubated for 2 h at room temperature with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (A6154, Sigma-Aldrich) diluted 1 / 2,000 in TBS-Tween-20. The secondary antibody was removed and the membrane was washed four times for 5 min in TBS-Tween-20. Blots were developed by enhanced chemiluminescence (ECL).A 1:1 mixture of WesternBright ECL Luminol / Enhancer solution and Peroxide Chemiluminescent solution (Advansta) was incubated for 2 min at room temperature and then added directly onto the washed blots. Chemiluminescence was detected using a LiCor C-Digit Blot Scanner over a 12 min exposure time.
[0176] result: The results are shown in Figure 6 and Table 13 below.
[0177] [Table 15]
[0178] Conclusion: A significant increase in occludin protein levels was observed in endothelial cell monolayers treated with 1, 10 and 100 μM NX218 compared to controls 24 hours after treatment (+26.3%, +41.1%, +36.8% for 1, 10 and 100 μM NX210c compared to controls, respectively, p=0.0309, p=0.0053, p=0.0112). Example 9
[0179] Effect of NX218 on transendothelial electrical resistance of primary human umbilical vein endothelial cell monolayers To determine the effect of NX218 on the transendothelial electrical resistance (TEER) of primary human umbilical vein endothelial cells (HUVECs), cells were grown in the presence or absence of NX218 on a semi-permeable membrane inserted into a culture well, and TEER was recorded using electrodes placed on either side of the membrane and a resistance meter.
[0180] Cell culture: HUVECs (PromoCell, C-12208) were cultured in EBM-2 basal medium supplemented with Bullet Kit reagents (both from Lonza) at 37°C in a 5% CO2 incubator.
[0181] TEER Measurement: HUVECs were grown on 6.5 mm diameter, 0.4 μm pore size polyester membrane HTS Transwell inserts (5 × 10 cells per well). 4 (each containing 200 μL and 800 μL of medium in the apical and basolateral compartments). Two days after seeding, cells were treated with vehicle or NX218 (1, 10 and 100 μM) for 1 or 3 days. TEER values were measured using an EVOM ohmmeter equipped with "chopstick" electrodes. One electrode was placed in the apical chamber and the other in the basolateral chamber. Before measurements, the chambers were replaced with fresh medium.
[0182] result: The results are shown in Tables 14 and 15 below.
[0183] [Table 16]
[0184] [Table 17]
[0185] Conclusion: Treatment of human umbilical vein endothelial cell monolayers with 100 μM NX218 for 1 or 3 days significantly increased resistance in a dose-dependent manner compared to vehicle-treated endothelial cell monolayers. References (hereby incorporated by reference): [References] TIFF2024543220000019.tif218170TIFF2024543220000020.tif218170TIFF2024543220000021.tif201170
Claims
1. Amino acid sequences for use in the treatment of biological barrier dysfunction X1-WS-A1-WS-A2-CS-A3-A4-CG-X2 (SEQ ID NO: 1) A peptide of the formula: During the ceremony, - A1, A2, A3 and A4 consist of an amino acid sequence consisting of 1 to 5 amino acids, - X1 and X2 consist of an amino acid sequence consisting of 1 to 6 amino acids, or X1 and X2 are absent; - the N-terminal amino acid can be acetylated, the C-terminal amino acid can be amidated, or the N-terminal amino acid can be acetylated and the C-terminal amino acid can be amidated; A peptide that reduces biological barrier permeability.
2. 2. The peptide for use according to claim 1, wherein the biological barrier dysfunction comprises alterations in tight junctions between adjacent cells forming the endothelial or epithelial layer of the biological barrier, a decrease in transendothelial and / or transepithelial electrical resistance, dysregulation of claudin-5 expression or distribution, and / or dysregulation of transcompartment permeability of certain compounds or molecules.
3. 3. The peptide for use according to claim 1 or 2, wherein the biological barrier is the blood-brain barrier, the blood-spinal fluid barrier, the blood-intraretinal barrier, the blood-cerebrospinal fluid barrier, the pulmonary endothelial barrier, the blood-parenchyma or the blood-fluid barrier.
4. 4. The peptide for use according to any one of claims 1 to 3, wherein the biological barrier dysfunction occurs in diseases or conditions including vascular disease, infectious diseases, hyperresponsive immune system, inflammatory or autoimmune diseases, chronic kidney disease, intestinal disease, macular degeneration, diabetic macular edema, epilepsy, CNS diseases and disorders, and aging.
5. 5. The peptide for use according to any one of claims 1 to 4, which has the amino acid sequence WS-A1-WS-A2-CS-A3-A4-CG (SEQ ID NO: 2), wherein A1, A2, A3 and A4 consist of an amino acid sequence consisting of 1 to 5 amino acids.
6. A1 is selected from G, V, S, P and A, preferably G and S; - A2 is selected from G, V, S, P and A, preferably G, S; A3 is selected from R, A and V, preferably R, V, and / or - A4 is selected from S, T, P and A, preferably S, T; A peptide for use according to any one of claims 1 to 5.
7. 7. The peptide for use according to any one of claims 1 to 6, wherein A1 and A2 are independently selected from G and S, and / or A3-A4 are selected from RS or VS or VT or RT.
8. A peptide for use according to any one of claims 1 to 7, which has a sequence selected from the group consisting of the sequences SEQ ID NO: 3 to 63.
9. 9. The peptide for use according to any one of claims 1 to 8, which is a linear or cyclic peptide in which the two cysteines occurring in the peptide formula of SEQ ID NO: 1 or 2 form a disulfide bridge.
10. 5. A peptide for use according to any one of claims 1 to 4, which is a peptide of sequence SEQ ID NO: 3, which is a linear or cyclic peptide in which the two cysteines form a disulfide bridge or is a mixture of both.
11. 5. The peptide for use according to any one of claims 1 to 4, which is a peptide of sequence SEQ ID NO: 3 and which is a cyclic peptide in which the two cysteines form a disulfide bridge.
12. A peptide for use according to any one of claims 1 to 11 for use in a patient determined to have impaired biological barrier function, altered tight junctions, abnormal expression levels or distribution of claudin-5, dysregulation of transendothelial and / or transepithelial electrical resistance at the level of the biological barrier, dysregulation of transcompartment permeability of certain compounds or molecules.
Citation Information
Patent Citations
Oligopeptides as antiangiogenic agents
JP2017538683A
Systemic administration of peptides for the treatment of spinal cord injury and / or for remyelination
WO2021069497A1
Peptide compositions and methods for treating tauopathies
WO2021110976A1
Peptides and polypeptides useful for regenerating the nervous system
US6995140B1
Novel peptides and polypeptides useful for regenerating the nervous system
WO1999003890A1
